Australia Canada Singapore Switzerland (ACSS) Consortium - New Chemical Entities Work Sharing Trial Phase I

Australia Canada Singapore Switzerland (ACSS) Consortium - New Chemical Entities Work Sharing Trial Phase I

Published on June 27, 2018

Author: Karen Zhou

The Australia Canada Singapore Switzerland (ACSS) Consortium was established to foster collaboration and synergy between regulatory authorities to address common scientific and regulatory challenges.  The consortium consists of several working groups with various projects that aim to address current regulatory issues such as timely access to safe therapeutic products within a limited resource capacity. 

The New Chemical Entities (NCE) Working Group was formed by ACSS as part of an effort to develop regulatory programs through a greater alignment of regulatory approaches and technical requirements, more efficient use of resources, and the establishment of an effective network among liked-minded regulators.  The group is launching a work-sharing trial for the coordinated assessment of NCE applications by Health Canada and TGA, with Singapore and Switzerland participating as observers. The joint assessment will focus on the evaluation phase only.  However, the joint assessment is not intended to replace the independent decision-making of each regulatory authority. The results of the initial trial provide the knowledge and experience that will strengthen understanding of regulatory procedures of each jurisdiction to enhance future collaborations. Among the potential benefits from this initiative is a decreased regulatory burden.

Health Canada and TGA are inviting applicants interested in this work-sharing trial to contact their domestic regulatory authority.  If you are an industry member interested in participating in the work-sharing trial, please contact the regional contact for Canada at: HC.tpd.international-dpt.SC@canada.ca

Reference:

Notice: Australia Canada Singapore Switzerland (ACSS) Consortium - New Chemical Entities Work Sharing Trial Phase I (April 30, 2018) https://www.canada.ca/en/health-canada/services/drugs-health-products/international-activities/notice-acss-new-chemical-entities-trial-phase-1.html

Related Articles

Artificial Intelligence – Revolutionizing the Healthcare Industry

Artificial Intelligence – Revolutionizing the Healthcare Industry

What is Artificial Intelligence? Artificial intelligence (AI) is a broad term for a category of algorithms and models that perform tasks and exhibit behaviors such as...

Technology Continues to Transform Healthcare and the Regulatory World

Technology Continues to Transform Healthcare and the Regulatory World

Introduction: Digital health solutions are advancing rapidly in the field of diagnostics, emergency response, hospital management. As the goal of individuals shifts more...

Rare Diseases and Orphan Drugs Regulatory Framework in Canada: Recent Initiatives by Government of Canada

Rare Diseases and Orphan Drugs Regulatory Framework in Canada: Recent Initiatives by Government of Canada

What are Rare Diseases and How do They Affect Canadians? According to Health Canada, rare diseases are life-threatening, debilitating, or serious and chronic conditions that...